Palvella Therapeutics Announces First Patient Dosed in SELVA Phase 3 Clinical Trial of QTORIN™ 3.9% Rapamycin Anhydrous Gel (QTORIN™ rapamycin) for the Treatment of Microcystic Lymphatic Malformations

Clinical Trial Announcement: Palvella Therapeutics has initiated a Phase 3 clinical trial (SELVA) for QTORIN™ 3.9% rapamycin anhydrous gel, targeting microcystic lymphatic malformations, with the first patient now dosed and enrollment ongoing at various U.S. centers.

Potential Impact: If successful, QTORIN™ rapamycin could become the first FDA-approved treatment for microcystic LMs, addressing a significant unmet medical need for over 30,000 patients in the U.S. suffering from this debilitating genetic condition.